Neuropsych Drugmaker Wants Out Of Investors' IPO Data Suit
By Emilie Ruscoe · March 13, 2026, 8:52 PM EDT
Neuropsychiatric drugmaker Neumora Therapeutics Inc. seeks to shed investor claims it mischaracterized certain clinical study data ahead of its September 2023 initial public offering, arguing that the trading price decline cited in...
To view the full article, register now.